

# Allopregnanolone as a mediator of affective switching in reproductive mood disorders

- [Crystal Edler Schiller](#)<sup>1</sup>✉,
- [Peter J. Schmidt](#)<sup>2</sup> &
- [David R. Rubinow](#)<sup>1</sup>

*Psychopharmacology* volume 231, pages3557–3567(2014)[Cite this article](#)

- 795 Accesses
- 50 Citations
- 6 Altmetric
- [Metrics details](#)

## Abstract

### Rationale

Reproductive mood disorders, including premenstrual dysphoria (PMD) and postpartum depression (PPD), are characterized by affective dysregulation that occurs during specific reproductive states. The occurrence of illness onset during changes in reproductive endocrine function has generated interest in the role of gonadal steroids in the pathophysiology of reproductive mood disorders, yet the mechanisms by which the changing hormone milieu triggers depression in susceptible women remain poorly understood.

### Objectives

This review focuses on one of the neurosteroid metabolites of progesterone — allopregnanolone (ALLO) — that acutely regulates neuronal function and may mediate affective dysregulation that occurs concomitant with changes in reproductive endocrine function. We describe the role of the “neuroactive” steroids estradiol and progesterone in reproductive endocrine-related mood disorders to highlight the potential mechanisms by which ALLO might contribute to their pathophysiology. Finally, using existing data, we test the hypothesis that changes in ALLO levels may trigger affective dysregulation in susceptible women.

## Results

Although there is no reliable evidence that basal ALLO levels distinguish those with PMD or PPD from those without, existing animal models suggest potential mechanisms by which specific reproductive states may unmask susceptibility to affective dysregulation. Consistent with these models, initially euthymic women with PMD and those with a history of PPD show a negative association between depressive symptoms and circulating ALLO levels following progesterone administration.

## Conclusions

Existing animal models and our own preliminary data suggest that ALLO may play an important role in the pathophysiology of reproductive mood disorders by triggering affective dysregulation in susceptible women.

This is a preview of subscription content, [log in](#) to check access.

Access options	
<p>Buy article PDF</p> <p><b>US\$ 39.95</b></p> <p>Price <b>includes VAT</b> for USA</p> <p>Instant access to the full article PDF.</p> <p><a href="#">Rent this article via DeepDyve.</a></p>	<p>Buy journal subscription</p> <p><b>US\$ 199</b></p> <p>This is the <b>net price</b>. Taxes to be calculated in checkout.</p> <p>Immediate online access to all issues from 2019. Subscription will auto renew annually.</p> <p><a href="#">Learn more about Institutional subscriptions</a></p>

**Fig. 1**

## References

1. Akwa Y, Purdy RH, Koob GF, Britton KT (1999) The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat. *Behav Brain Res* 106:119–125. doi:[10.1016/S0166-4328\(99\)00101-1](https://doi.org/10.1016/S0166-4328(99)00101-1)  
[CAS](#) [PubMed](#) [Google Scholar](#)

- American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th ed. American Psychiatric Publishing, Arlington

[Google Scholar](#)

- Baehr E, Rosenfeld P, Miller L, Baehr R (2004) Premenstrual dysphoric disorder and changes in frontal alpha asymmetry. *Int J Psychophysiol Off J Int Organ Psychophysiol* 52:159–167. doi:[10.1016/j.jpsycho.2003.06.002](https://doi.org/10.1016/j.jpsycho.2003.06.002)

[Google Scholar](#)

- Baller EB, Wei S-M, Kohn PD et al (2013) Abnormalities of dorsolateral prefrontal function in women with premenstrual dysphoric disorder: a multimodal neuroimaging study. *Am J Psychiatry* 170:305–314. doi:[10.1176/appi.ajp.2012.12030385](https://doi.org/10.1176/appi.ajp.2012.12030385)

[PubMed Central](#) [PubMed](#) [Google Scholar](#)

- Bannbers E, Gingnell M, Engman J et al (2012) The effect of premenstrual dysphoric disorder and menstrual cycle phase on brain activity during response inhibition. *J Affect Disord* 142:347–350. doi:[10.1016/j.jad.2012.04.006](https://doi.org/10.1016/j.jad.2012.04.006)

[PubMed](#) [Google Scholar](#)

- Barbaccia ML, Roscetti G, Trabucchi M et al (1997) The effects of inhibitors of GABAergic transmission and stress on brain and plasma allopregnanolone concentrations. *Br J Pharmacol* 120:1582–1588. doi:[10.1038/sj.bjp.0701046](https://doi.org/10.1038/sj.bjp.0701046)

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

- Belelli D, Lambert JJ (2005) Neurosteroids: endogenous regulators of the GABAA receptor. *Nat Rev Neurosci* 6:565–575. doi:[10.1038/nrn1703](https://doi.org/10.1038/nrn1703)

[CAS](#) [PubMed](#) [Google Scholar](#)

- Berman KF, Schmidt PJ, Rubinow DR et al (1997) Modulation of cognition-specific cortical activity by gonadal steroids: a positron-emission tomography study in women. *Proc Natl Acad Sci U S A* 94:8836–8841

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

- Bičíková M, Dibbelt L, Hiill M et al (2007) Allopregnanolone in women with premenstrual syndrome. *Horm Metab Res* 30:227–229. doi:[10.1055/s-2007-978871](https://doi.org/10.1055/s-2007-978871)

[Google Scholar](#)

- Bitran D, Hilvers RJ, Kellogg CK (1991) Anxiolytic effects of 3 $\alpha$ -hydroxy-5 $\alpha$ [ $\beta$ ]-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. *Brain Res* 561:157–161. doi:[10.1016/0006-8993\(91\)90761-J](https://doi.org/10.1016/0006-8993(91)90761-J)

[CAS](#) [PubMed](#) [Google Scholar](#)

- Bitran D, Purdy RH, Kellogg CK (1993) Anxiolytic effect of progesterone is associated with increases in cortical alloprenanolone and GABAA receptor function. *Pharmacol Biochem Behav* 45:423–428. doi:[10.1016/0091-3057\(93\)90260-Z](https://doi.org/10.1016/0091-3057(93)90260-Z)

[CAS](#) [PubMed](#) [Google Scholar](#)

12. Bixo M, Andersson A, Winblad B et al (1997) Progesterone, 5 $\alpha$ -pregnane-3,20-dione and 3 $\alpha$ -hydroxy-5 $\alpha$ -pregnane-20-one in specific regions of the human female brain in different endocrine states. *Brain Res* 764:173–178. doi:[10.1016/S0006-8993\(97\)00455-1](https://doi.org/10.1016/S0006-8993(97)00455-1)  
[CAS](#) [PubMed](#) [Google Scholar](#)
13. Bloch M, Schmidt PJ, Danaceau M et al (2000) Effects of gonadal steroids in women with a history of postpartum depression. *Am J Psychiatry* 157:924–930  
[CAS](#) [PubMed](#) [Google Scholar](#)
14. Bortolato M, Devoto P, Roncada P et al (2011) Isolation rearing-induced reduction of brain 5 $\alpha$ -reductase expression: relevance to dopaminergic impairments. *Neuropharmacology* 60:1301–1308. doi:[10.1016/j.neuropharm.2011.01.013](https://doi.org/10.1016/j.neuropharm.2011.01.013)  
[CAS](#) [PubMed](#) [Google Scholar](#)
15. Cardona-Gomez P, Perez M, Avila J et al (2004) Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus. *Mol Cell Neurosci* 25:363–373. doi:[10.1016/j.mcn.2003.10.008](https://doi.org/10.1016/j.mcn.2003.10.008)  
[CAS](#) [PubMed](#) [Google Scholar](#)
16. Carver CM, Reddy DS (2013) Neurosteroid interactions with synaptic and extrasynaptic GABAA receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability. *Psychopharmacology (Berl)* 230:151–188. doi:[10.1007/s00213-013-3276-5](https://doi.org/10.1007/s00213-013-3276-5)  
[CAS](#) [Google Scholar](#)
17. Davidson RJ (1998) Anterior electrophysiological asymmetries, emotion, and depression: conceptual and methodological conundrums. *Psychophysiology* 35:607–614  
[CAS](#) [PubMed](#) [Google Scholar](#)
18. Deeks AA, Gibson-Helm ME, Teede HJ (2010) Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation. *Fertil Steril* 93:2421–2423. doi:[10.1016/j.fertnstert.2009.09.018](https://doi.org/10.1016/j.fertnstert.2009.09.018)  
[PubMed](#) [Google Scholar](#)
19. Deligiannidis KM, Sikoglu EM, Shaffer SA et al (2013) GABAergic neuroactive steroids and resting-state functional connectivity in postpartum depression: a preliminary study. *J Psychiatr Res* 47:816–828. doi:[10.1016/j.jpsychires.2013.02.010](https://doi.org/10.1016/j.jpsychires.2013.02.010)  
[PubMed Central](#) [PubMed](#) [Google Scholar](#)
20. Djebaili M, Guo Q, Pettus EH et al (2005) The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. *J Neurotrauma* 22:106–118. doi:[10.1089/neu.2005.22.106](https://doi.org/10.1089/neu.2005.22.106)  
[PubMed](#) [Google Scholar](#)
21. Dowlati Y, Herrmann N, Swardfager W et al (2010) A meta-analysis of cytokines in major depression. *Biol Psychiatry* 67:446–457. doi:[10.1016/j.biopsych.2009.09.033](https://doi.org/10.1016/j.biopsych.2009.09.033)  
[CAS](#) [PubMed](#) [Google Scholar](#)

22. Dreher JC, Schmidt PJ, Kohn P et al (2007) Menstrual cycle phase modulates reward-related neural function in women. *Proc Natl Acad Sci U S A* 104(2465)
23. Dubrovsky B (2006) Neurosteroids, neuroactive steroids, and symptoms of affective disorders. *Pharmacol Biochem Behav* 84:644–655. doi:[10.1016/j.pbb.2006.06.016](https://doi.org/10.1016/j.pbb.2006.06.016)  
[CAS](#) [PubMed](#) [Google Scholar](#)
24. Epperson C, Haga K, Mason G et al (2002) Cortical  $\gamma$ -aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. *Arch Gen Psychiatry* 59:851–858. doi:[10.1001/archpsyc.59.9.851](https://doi.org/10.1001/archpsyc.59.9.851)  
[CAS](#) [PubMed](#) [Google Scholar](#)
25. Epperson CN, Gueorguieva R, Czarkowski KA et al (2006) Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a  $^1\text{H}$ -MRS study. *Psychopharmacology (Berl)* 186:425–433. doi:[10.1007/s00213-006-0313-7](https://doi.org/10.1007/s00213-006-0313-7)  
[CAS](#) [Google Scholar](#)
26. Epperson CN, Steiner M, Hartlage SA et al (2012) Premenstrual dysphoric disorder: evidence for a new category for DSM-5. *Am J Psychiatry* 169:465–475  
[PubMed Central](#) [PubMed](#) [Google Scholar](#)
27. Eser D, Schüle C, Baghai TC et al (2006) Neuroactive steroids in depression and anxiety disorders: clinical studies. *Neuroendocrinology* 84:244–254. doi:[10.1159/000097879](https://doi.org/10.1159/000097879)  
[CAS](#) [PubMed](#) [Google Scholar](#)
28. Evans J, Sun Y, McGregor A, Connor B (2012) Allopregnanolone regulates neurogenesis and depressive/anxiety-like behaviour in a social isolation rodent model of chronic stress. *Neuropharmacology* 63:1315–1326. doi:[10.1016/j.neuropharm.2012.08.012](https://doi.org/10.1016/j.neuropharm.2012.08.012)  
[CAS](#) [PubMed](#) [Google Scholar](#)
29. Fassnacht M, Schlenz N, Schneider SB et al (2003) Beyond adrenal and ovarian androgen generation: increased peripheral  $5\alpha$ -reductase activity in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 88:2760–2766. doi:[10.1210/jc.2002-021875](https://doi.org/10.1210/jc.2002-021875)  
[CAS](#) [PubMed](#) [Google Scholar](#)
30. Finocchi C, Ferrari M (2011) Female reproductive steroids and neuronal excitability. *Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol* 32(Suppl 1):S31–S35. doi:[10.1007/s10072-011-0532-5](https://doi.org/10.1007/s10072-011-0532-5)  
[Google Scholar](#)
31. Foy MR, Baudry M, Akopian GK, Thompson RF (2010) Regulation of hippocampal synaptic plasticity by estrogen and progesterone. *Vitam Horm* 82:219–239. doi:[10.1016/S0083-6729\(10\)82012-6](https://doi.org/10.1016/S0083-6729(10)82012-6)  
[CAS](#) [PubMed](#) [Google Scholar](#)
32. Freeman E, Rickels K, Sondheimer S, Polansky M (1990) Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. *JAMA* 264:349–353. doi:[10.1001/jama.1990.03450030073035](https://doi.org/10.1001/jama.1990.03450030073035)  
[CAS](#) [PubMed](#) [Google Scholar](#)

33. Freeman E, Rickels K, Sondheimer S, Polansky M (1995) A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. *JAMA* 274:51–57. doi:[10.1001/jama.1995.03530010065036](https://doi.org/10.1001/jama.1995.03530010065036)
- [CAS](#) [PubMed](#) [Google Scholar](#)
34. Freeman EW, Frye CA, Rickels K et al (2002) Allopregnanolone levels and symptom improvement in severe premenstrual syndrome. *J Clin Psychopharmacol* 22:516–520
- [CAS](#) [PubMed](#) [Google Scholar](#)
35. Frye CA (2009) Neurosteroids' effects and mechanisms for social, cognitive, emotional, and physical functions. *Psychoneuroendocrinology* 1:S143–S161. doi:[10.1016/j.psyneuen.2009.07.005](https://doi.org/10.1016/j.psyneuen.2009.07.005)
- [Google Scholar](#)
36. Frye CA, Duncan JE (1994) Progesterone metabolites, effective at the GABAA receptor complex, attenuate pain sensitivity in rats. *Brain Res* 643:194–203. doi:[10.1016/0006-8993\(94\)90025-6](https://doi.org/10.1016/0006-8993(94)90025-6)
- [CAS](#) [PubMed](#) [Google Scholar](#)
37. Gavin NI, Gaynes BN, Lohr KN et al (2005) Perinatal depression: a systematic review of prevalence and incidence. *Obstet Gynecol* 106:1071
- [PubMed](#) [Google Scholar](#)
38. Genazzani AR, Petraglia F, Bernardi F et al (1998) Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. *J Clin Endocrinol Metab* 83:2099–2103. doi:[10.1210/jc.83.6.2099](https://doi.org/10.1210/jc.83.6.2099)
- [CAS](#) [PubMed](#) [Google Scholar](#)
39. Gilbert Evans SE, Ross LE, Sellers EM et al (2005) 3alpha-reduced neuroactive steroids and their precursors during pregnancy and the postpartum period. *Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol* 21:268–279. doi:[10.1080/09513590500361747](https://doi.org/10.1080/09513590500361747)
- [CAS](#) [Google Scholar](#)
40. Gingnell M, Morell A, Bannbers E et al (2012) Menstrual cycle effects on amygdala reactivity to emotional stimulation in premenstrual dysphoric disorder. *Horm Behav* 62:400–406. doi:[10.1016/j.yhbeh.2012.07.005](https://doi.org/10.1016/j.yhbeh.2012.07.005)
- [PubMed](#) [Google Scholar](#)
41. Girdler SS, Straneva PA, Light KC et al (2001) Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. *Biol Psychiatry* 49:788–797
- [CAS](#) [PubMed](#) [Google Scholar](#)
42. Glantz LA, Gilmore JH, Overstreet DH et al (2010) Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression. *Schizophr Res* 118:292–299. doi:[10.1016/j.schres.2009.12.027](https://doi.org/10.1016/j.schres.2009.12.027)
- [PubMed Central](#) [PubMed](#) [Google Scholar](#)
43. Goldstein JM, Jerram M, Poldrack R et al (2005) Hormonal cycle modulates arousal circuitry in women using functional magnetic resonance imaging. *J Neurosci Off J Soc Neurosci* 25:9309–9316. doi:[10.1523/JNEUROSCI.2239-05.2005](https://doi.org/10.1523/JNEUROSCI.2239-05.2005)

[CAS](#) [Google Scholar](#)

44. Gotlib IH, Whiffen VE, Mount JH et al (1989) Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. *J Consult Clin Psychol* 57:269–274. doi:[10.1037/0022-006X.57.2.269](https://doi.org/10.1037/0022-006X.57.2.269)

[CAS](#) [PubMed](#) [Google Scholar](#)

45. Griffin LD, Mellon SH (1999) Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. *Proc Natl Acad Sci* 96:13512–13517. doi:[10.1073/pnas.96.23.13512](https://doi.org/10.1073/pnas.96.23.13512)

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

46. Guintivano J, Arad M, Gould TD et al (2013) Antenatal prediction of postpartum depression with blood DNA methylation biomarkers. *Mol Psychiatry*. doi:[10.1038/mp.2013.62](https://doi.org/10.1038/mp.2013.62)

[PubMed](#) [Google Scholar](#)

47. He J, Evans C-O, Hoffman SW et al (2004) Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. *Exp Neurol* 189:404–412. doi:[10.1016/j.expneurol.2004.06.008](https://doi.org/10.1016/j.expneurol.2004.06.008)

[CAS](#) [PubMed](#) [Google Scholar](#)

48. Huo L, Straub RE, Roca C et al (2007) Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. *Biol Psychiatry* 62:925–933. doi:[10.1016/j.biopsych.2006.12.019](https://doi.org/10.1016/j.biopsych.2006.12.019)

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

49. Kehoe P, Mallinson K, McCormick CM, Frye CA (2000) Central allopregnanolone is increased in rat pups in response to repeated, short episodes of neonatal isolation. *Dev Brain Res* 124:133–136. doi:[10.1016/S0165-3806\(00\)00106-1](https://doi.org/10.1016/S0165-3806(00)00106-1)

[CAS](#) [Google Scholar](#)

50. Klatzkin RR, Leslie Morrow A, Light KC et al (2006) Associations of histories of depression and PMDD diagnosis with allopregnanolone concentrations following the oral administration of micronized progesterone. *Psychoneuroendocrinology* 31:1208–1219. doi:[10.1016/j.psyneuen.2006.09.002](https://doi.org/10.1016/j.psyneuen.2006.09.002)

[CAS](#) [PubMed](#) [Google Scholar](#)

51. Lawrie TA, Herxheimer A, Dalton K (2000) Oestrogens and progestogens for preventing and treating postnatal depression. *Cochrane Database Syst Rev* CD001690. doi: [10.1002/14651858.CD001690](https://doi.org/10.1002/14651858.CD001690)

52. Licinio J, Wong ML (1999) The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. *Mol Psychiatry* 4:317–327

[CAS](#) [PubMed](#) [Google Scholar](#)

53. MacKenzie G, Maguire J The role of ovarian hormone-derived neurosteroids on the regulation of GABAA receptors in affective disorders. *Psychopharmacology (Berl)* 1–10. doi: [10.1007/s00213-013-3423-z](https://doi.org/10.1007/s00213-013-3423-z)

54. Maguire J, Mody I (2008) GABAAR plasticity during pregnancy: relevance to postpartum depression. *Neuron* 59:207–213. doi:[10.1016/j.neuron.2008.06.019](https://doi.org/10.1016/j.neuron.2008.06.019)

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

55. Maguire JL, Stell BM, Rafizadeh M, Mody I (2005) Ovarian cycle-linked changes in GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and anxiety. *Nat Neurosci* 8:797–804

[CAS](#) [PubMed](#) [Google Scholar](#)

56. Maguire J, Ferando I, Simonsen C, Mody I (2009) Excitability changes related to GABAA receptor plasticity during pregnancy. *J Neurosci* 29:9592–9601. doi:[10.1523/JNEUROSCI.2162-09.2009](#)

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

57. Mahon P, Payne J, MacKinnon D et al (2009) Genome-wide linkage and follow-up association study of postpartum mood symptoms. *Am J Psychiatry* 166:1229–1237. doi:[10.1176/appi.ajp.2009.09030417](#)

[PubMed Central](#) [PubMed](#) [Google Scholar](#)

58. Majewska MD, Harrison NL, Schwartz RD et al (1986) Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. *Science* 232:1004–1007

[CAS](#) [PubMed](#) [Google Scholar](#)

59. Matsui D, Sakari M, Sato T et al (2002) Transcriptional regulation of the mouse steroid 5 $\alpha$ -reductase type II gene by progesterone in brain. *Nucleic Acids Res* 30:1387–1393. doi:[10.1093/nar/30.6.1387](#)

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

60. McEwen BS (2002) Basic neurobiology of ovarian steroids: clinical implications. *Dialogues Clin Neurosci* 4:163–176

[Google Scholar](#)

61. Monteleone P, Luisi S, Tonetti A et al (2000) Allopregnanolone concentrations and premenstrual syndrome. *Eur J Endocrinol Eur Fed Endocr Soc* 142:269–273

[CAS](#) [Google Scholar](#)

62. Morrow AL, Devaud LL, Purdy RH, Paul SM (1995) Neuroactive steroid modulators of the stress response. *Ann N Y Acad Sci* 771:257–272. doi:[10.1111/j.1749-6632.1995.tb44687.x](#)

[CAS](#) [PubMed](#) [Google Scholar](#)

63. Moses-Kolko EL, Perlman SB, Wisner KL et al (2010) Abnormally reduced dorsomedial prefrontal cortical activity and effective connectivity with amygdala in response to negative emotional faces in postpartum depression. *Am J Psychiatry* 167:1373–1380

[PubMed Central](#) [PubMed](#) [Google Scholar](#)

64. Moses-Kolko EL, Fraser D, Wisner KL et al (2011) Rapid habituation of ventral striatal response to reward receipt in postpartum depression. *Biol Psychiatry* 70:395–399

[PubMed Central](#) [PubMed](#) [Google Scholar](#)

65. O'Hara MW, Swain AM (1996) Rates and risk of postpartum depression—a meta-analysis. *Int Rev Psychiatry* 8:37–54. doi:[10.3109/09540269609037816](#)

[Google Scholar](#)



66. Patchev VK, Shoaib M, Holsboer F, Almeida OFX (1994) The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. *Neuroscience* 62:265–271. doi:[10.1016/0306-4522\(94\)90330-1](https://doi.org/10.1016/0306-4522(94)90330-1)
- [CAS](#) [PubMed](#) [Google Scholar](#)
67. Patchev VK, Hassan AHS, Holsboer F, Almeida OFX (1996) The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. *Neuropsychopharmacology* 15:533–540. doi:[10.1016/S0893-133X\(96\)00096-6](https://doi.org/10.1016/S0893-133X(96)00096-6)
- [CAS](#) [PubMed](#) [Google Scholar](#)
68. Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA (2005) Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. *J Affect Disord* 85:275–282. doi:[10.1016/j.jad.2004.10.004](https://doi.org/10.1016/j.jad.2004.10.004)
- [PubMed](#) [Google Scholar](#)
69. Pluchino N, Russo M, Santoro AN et al (2013) Steroid hormones and BDNF. *Neuroscience* 239:271–279. doi:[10.1016/j.neuroscience.2013.01.025](https://doi.org/10.1016/j.neuroscience.2013.01.025)
- [CAS](#) [PubMed](#) [Google Scholar](#)
70. Protopopescu X, Pan H, Altemus M et al (2005) Orbitofrontal cortex activity related to emotional processing changes across the menstrual cycle. *Proc Natl Acad Sci U S A* 102:16060–16065. doi:[10.1073/pnas.0502818102](https://doi.org/10.1073/pnas.0502818102)
- [CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)
71. Protopopescu X, Tuescher O, Pan H et al (2008) Toward a functional neuroanatomy of premenstrual dysphoric disorder. *J Affect Disord* 108:87–94. doi:[10.1016/j.jad.2007.09.015](https://doi.org/10.1016/j.jad.2007.09.015)
- [PubMed](#) [Google Scholar](#)
72. Rapkin AJ, Morgan M, Goldman L et al (1997) Progesterone metabolite allopregnanolone in women with premenstrual syndrome. *Obstet Gynecol* 90:709–714. doi:[10.1016/S0029-7844\(97\)00417-1](https://doi.org/10.1016/S0029-7844(97)00417-1)
- [CAS](#) [PubMed](#) [Google Scholar](#)
73. Rapkin AJ, Berman SM, Mandelkern MA et al (2011) Neuroimaging evidence of cerebellar involvement in premenstrual dysphoric disorder. *Biol Psychiatry* 69:374–380. doi:[10.1016/j.biopsych.2010.09.029](https://doi.org/10.1016/j.biopsych.2010.09.029)
- [PubMed Central](#) [PubMed](#) [Google Scholar](#)
74. Romeo E, Ströhle A, Spalletta G et al (1998) Effects of antidepressant treatment on neuroactive steroids in major depression. *Am J Psychiatry* 155:910–913
- [CAS](#) [PubMed](#) [Google Scholar](#)
75. Rubinow DR, Girdler SS (2011) Hormones, heart disease, and health: individualized medicine versus throwing the baby out with the bathwater. *Depress Anxiety* 28:282–296. doi:[10.1002/da.20810](https://doi.org/10.1002/da.20810)
- [PubMed](#) [Google Scholar](#)
76. Sampson GA (1979) Premenstrual syndrome: a double-blind controlled trial of progesterone and placebo. *Br J Psychiatry* 135:209–215. doi:[10.1192/bjp.135.3.209](https://doi.org/10.1192/bjp.135.3.209)

[CAS](#) [PubMed](#) [Google Scholar](#)

77. Sayeed I, Parvez S, Wali B et al (2009) Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism for better neuroprotective effects of allopregnanolone over progesterone. *Brain Res* 1263:165–173. doi:[10.1016/j.brainres.2009.01.045](https://doi.org/10.1016/j.brainres.2009.01.045)

[CAS](#) [PubMed](#) [Google Scholar](#)

78. Schmidt PJ, Purdy RH, Moore PH et al (1994) Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. *J Clin Endocrinol Metab* 79:1256–1260. doi:[10.1210/jc.79.5.1256](https://doi.org/10.1210/jc.79.5.1256)

[CAS](#) [PubMed](#) [Google Scholar](#)

79. Schmidt PJ, Nieman LK, Danaceau MA et al (1998) Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. *N Engl J Med* 338:209–216. doi:[10.1056/NEJM199801223380401](https://doi.org/10.1056/NEJM199801223380401)

[CAS](#) [PubMed](#) [Google Scholar](#)

80. Schüle C, Romeo E, Uzunov DP et al (2005) Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3 $\alpha$ -hydroxysteroid dehydrogenase activity. *Mol Psychiatry* 11:261–272. doi:[10.1038/sj.mp.4001782](https://doi.org/10.1038/sj.mp.4001782)

[Google Scholar](#)

81. Schüle C, Baghai TC, di Michele F et al (2007) Effects of combination treatment with mood stabilizers and mirtazapine on plasma concentrations of neuroactive steroids in depressed patients. *Psychoneuroendocrinology* 32:669–680. doi:[10.1016/j.psyneuen.2007.04.004](https://doi.org/10.1016/j.psyneuen.2007.04.004)

[PubMed](#) [Google Scholar](#)

82. Schüle C, Eser D, Baghai TC et al (2011) Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? *Neuroscience* 191:55–77. doi:[10.1016/j.neuroscience.2011.03.025](https://doi.org/10.1016/j.neuroscience.2011.03.025)

[PubMed](#) [Google Scholar](#)

83. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M et al (2011) Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. *Mol Psychiatry* 16:751–762. doi:[10.1038/mp.2010.52](https://doi.org/10.1038/mp.2010.52)

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

84. Shen H, Gong QH, Aoki C et al (2007) Reversal of neurosteroid effects at  $\alpha 4\beta 2\delta$  GABAA receptors triggers anxiety at puberty. *Nat Neurosci* 10:469–477. doi:[10.1038/nn1868](https://doi.org/10.1038/nn1868)

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

85. Shimizu E, Hashimoto K, Okamura N et al (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. *Biol Psychiatry* 54:70–75. doi:[10.1016/S0006-3223\(03\)00181-1](https://doi.org/10.1016/S0006-3223(03)00181-1)

[CAS](#) [PubMed](#) [Google Scholar](#)

86. Silverman ME, Loudon H, Safier M et al (2007) Neural dysfunction in postpartum depression: an fMRI pilot study. *CNS Spectr* 12:853–862

[PubMed](#) [Google Scholar](#)

87. Smith SS, Gong QH, Hsu FC et al (1998a) GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid. *Nature* 392:926–930

[CAS](#) [PubMed](#) [Google Scholar](#)

88. Smith SS, Gong QH, Li X et al (1998b) Withdrawal from 3 $\alpha$ -OH-5 $\alpha$ -pregnan-20-one using a pseudopregnancy model alters the kinetics of hippocampal GABAA-gated current and increases the GABAA receptor  $\alpha$ 4 subunit in association with increased anxiety. *J Neurosci* 18:5275–5284

[CAS](#) [PubMed](#) [Google Scholar](#)

89. Smith MJ, Adams LF, Schmidt PJ et al (2002) Effects of ovarian hormones on human cortical excitability. *Ann Neurol* 51:599–603. doi:[10.1002/ana.10180](https://doi.org/10.1002/ana.10180)

[CAS](#) [PubMed](#) [Google Scholar](#)

90. Smith MJ, Adams LF, Schmidt PJ et al (2003) Abnormal luteal phase excitability of the motor cortex in women with premenstrual syndrome. *Biol Psychiatry* 54:757–762. doi:[10.1016/S0006-3223\(02\)01924-8](https://doi.org/10.1016/S0006-3223(02)01924-8)

[CAS](#) [PubMed](#) [Google Scholar](#)

91. Smith SS, Ruderman Y, Frye C et al (2006) Steroid withdrawal in the mouse results in anxiogenic effects of 3 $\alpha$ ,5 $\beta$ -THP: a possible model of premenstrual dysphoric disorder. *Psychopharmacology (Berl)* 186:323–333. doi:[10.1007/s00213-005-0168-3](https://doi.org/10.1007/s00213-005-0168-3)

[CAS](#) [Google Scholar](#)

92. Sohrabji F, Greene LA, Miranda RC, Toran-Allerand CD (1994a) Reciprocal regulation of estrogen and NGF receptors by their ligands in PC12 cells. *J Neurobiol* 25:974–988. doi:[10.1002/neu.480250807](https://doi.org/10.1002/neu.480250807)

[CAS](#) [PubMed](#) [Google Scholar](#)

93. Sohrabji F, Miranda RC, Toran-Allerand CD (1994b) Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. *J Neurosci Off J Soc Neurosci* 14:459–471

[CAS](#) [Google Scholar](#)

94. Sorwell KG, Kohama SG, Urbanski HF (2012) Perimenopausal regulation of steroidogenesis in the nonhuman primate. *Neurobiol Aging* 33:1487.e1–1487.e13. doi:[10.1016/j.neurobiolaging.2011.05.0](https://doi.org/10.1016/j.neurobiolaging.2011.05.0)

[CAS](#) [Google Scholar](#)

95. Ströhle A, Romeo E, Hermann B et al (1999) Concentrations of 3 $\alpha$ -reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. *Biol Psychiatry* 45:274–277. doi:[10.1016/S0006-3223\(98\)00328-X](https://doi.org/10.1016/S0006-3223(98)00328-X)

[PubMed](#) [Google Scholar](#)

96. Sundström Poromaa I, Smith S, Gulinello M (2003) GABA receptors, progesterone and premenstrual dysphoric disorder. *Arch Womens Ment Health* 6:23–41. doi:[10.1007/s00737-002-0147-1](https://doi.org/10.1007/s00737-002-0147-1)

[PubMed](#) [Google Scholar](#)

97. Sundström I, Bäckström T (1998) Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. *Psychoneuroendocrinology* 23:73–88. doi:[10.1016/S0306-](https://doi.org/10.1016/S0306-)

[4530\(97\)00064-4](#)

[PubMed](#) [Google Scholar](#)

98. Sundström I, Nyberg S, Bäckström T (1997) Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. *Neuropsychopharmacology* 17:370–381. doi:[10.1016/S0893-133X\(97\)00086-9](#)

[PubMed](#) [Google Scholar](#)

99. Sundström I, Andersson A, Nyberg S et al (1998) Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. *Neuroendocrinology* 67:126–138. doi:[10.1159/000054307](#)

[PubMed](#) [Google Scholar](#)

100. Taniguchi F, Couse JF, Rodriguez KF et al (2007) Estrogen receptor- $\alpha$  mediates an intraovarian negative feedback loop on thecal cell steroidogenesis via modulation of Cyp17a1 (cytochrome P450, steroid 17 $\alpha$ -hydroxylase/17,20 lyase) expression. *FASEB J* 21:586–595. doi:[10.1096/fj.06-6681.com](#)

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

101. Tiemstra JD, Patel K (1998) Hormonal therapy in the management of premenstrual syndrome. *J Am Board Fam Pract* 11:378–381. doi:[10.3122/15572625-11-5-378](#)

[CAS](#) [PubMed](#) [Google Scholar](#)

102. Tomarken AJ, Dichter GS, Garber J, Simien C (2004) Resting frontal brain activity: linkages to maternal depression and socio-economic status among adolescents. *Biol Psychol* 67:77–102. doi:[10.1016/j.biopsycho.2004.03.011](#)

[PubMed](#) [Google Scholar](#)

103. Tuohy A, McVey C (2008) Subscales measuring symptoms of non-specific depression, anhedonia, and anxiety in the Edinburgh Postnatal Depression Scale. *Br J Clin Psychol* 47:153–169

[PubMed](#) [Google Scholar](#)

104. Uzunov DP, Cooper TB, Costa E, Guidotti A (1996) Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. *Proc Natl Acad Sci* 93:12599–12604

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

105. Uzunova V, Sheline Y, Davis JM et al (1998) Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. *Proc Natl Acad Sci* 95:3239–3244

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

106. Walf AA, Frye CA (2006) A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. *Neuropsychopharmacology* 31:1097–1111

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

107. Wang M, Seippel L, Purdy RH, Bäckström T (1996) Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5

alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one. J Clin Endocrinol Metab 81:1076–1082. doi:[10.1210/jc.81.3.1076](https://doi.org/10.1210/jc.81.3.1076)

[CAS](#) [PubMed](#) [Google Scholar](#)

108. Wieland S, Lan NC, Mirasedeghi S, Gee KW (1991) Anxiolytic activity of the progesterone metabolite 5 $\alpha$ -pregnan-3 $\alpha$ -ol-20-one. Brain Res 565:263–268. doi:[10.1016/0006-8993\(91\)91658-N](https://doi.org/10.1016/0006-8993(91)91658-N)

[CAS](#) [PubMed](#) [Google Scholar](#)

109. Zhou Y, Watters JJ, Dorsa DM (1996) Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology 137:2163–2166. doi:[10.1210/en.137.5.2163](https://doi.org/10.1210/en.137.5.2163)

[CAS](#) [PubMed](#) [Google Scholar](#)

[Download references](#) ↓

## Author information

### Affiliations

1. Department of Psychiatry, University of North Carolina at Chapel Hill, 250 Medical School Wing D, Campus Box #7175, Chapel Hill, NC, 27599-7175, USA

Crystal Edler Schiller & David R. Rubinow

2. NIMH, Department of Health and Human Services, Section on Behavioral Endocrinology, Bethesda, MD, USA

Peter J. Schmidt

### Authors

1. Crystal Edler Schiller

[View author publications](#)

You can also search for this author in [PubMed](#) [Google Scholar](#)

2. Peter J. Schmidt

[View author publications](#)

You can also search for this author in [PubMed](#) [Google Scholar](#)

3. David R. Rubinow

[View author publications](#)

You can also search for this author in [PubMed](#) [Google Scholar](#)

### Corresponding author

Correspondence to [Crystal Edler Schiller](#).

## Rights and permissions

[Reprints and Permissions](#)